image: Prof. Zefei Jiang, Director of the Department of Breast Cancer, 307th Hospital of PLA (AMMS China) in Beijing, China, study author. view more
Credit: © European Society for Medical Oncology
Munich, Germany, 20 October 2018 - Epigenetic therapy with histone deacetylase (HDAC) inhibitors is worth pursuing in hormone receptor positive advanced breast cancer, suggests a phase III trial (1) reported today at the ESMO 2018 Congress in Munich.
Endocrine therapies are the foundation of treatment for patients with hormone receptor positive breast cancer. However, resistance to endocrine therapy is common, leading to disease progression or recurrence. HDAC inhibitors are a type of epigenetic therapy, meaning that they can switch genes on or off without changing the underlying DNA sequence. HDAC inhibitors have previously been shown to reverse resistance to hormone therapy. (2) But no randomised trial has so far demonstrated superiority with an HDAC inhibitor over existing treatments in advanced breast cancer.
This phase III trial used chidamide, an HDAC inhibitor developed in China. The study enrolled 365 postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer from 22 centres in China. Patients had progressed on previous endocrine therapy (tamoxifen and/or a nonsteroidal aromatase inhibitor). Patients were randomly allocated in a 2:1 ratio to receive chidamide 30 mg twice a week plus endocrine therapy with exemestane 25 mg daily (a steroidal aromatase inhibitor) or placebo plus exemestane.
The median progression free survival was 7.4 months with chidamide plus exemestane and 3.8 months with placebo plus exemestane (hazard ratio for disease progression or death 0.755, 95% confidence interval 0.582-0.978, p=0.0336). Prof. Zefei Jiang, Director of the Department of Breast Cancer, 307th Hospital of PLA (AMMS China) in Beijing, China, said: "This is the first phase III trial to demonstrate that an HDAC inhibitor plus endocrine blockade improves progression free survival compared to endocrine blockade alone in hormone receptor positive advanced breast cancer patients who have progressed after prior endocrine therapy."
Serious adverse events occurred in 51 (20.9%) patients in the chidamide group and seven (5.8%) in the placebo group. These included reduced blood levels of neutrophils (50.8% versus 2.5%), platelets (27.5% versus 2.5%), and leukocytes (18.8% versus 2.5%) in the chidamide and placebo groups, respectively. There were no deaths due to chidamide.
Quality of life with the drug was not measured in the study, but Jiang said: "The treatment regimen was generally well tolerated and toxicities were similar to those previously observed with chidamide monotherapy. The most common adverse events were blood disorders which were mostly asymptomatic and manageable."
Commenting on the study, Dr. Suzette Delaloge, Head, Breast Cancer Group, Institut Gustave Roussy, Paris, France, said: "This is the first randomised phase III trial to reach a positive result with an HDAC inhibitor in advanced breast cancer. It suggests that there may be some hope for this type of drug in these patients, since until now the only positive results have been in earlier stage breast cancer."
Delaloge said the findings should prompt more research on HDAC inhibitors in patients with advanced breast cancer. She said: "Studies are needed in Western populations comparing an HDAC inhibitor to the standard of care, which is the combination of endocrine therapy plus an m-TOR inhibitor (everolimus) or the combination of an endocrine therapy plus a CDK4/6 inhibitor."
On top of this trial, two ongoing phase III studies are comparing exemestane plus the HDAC inhibitor entinostat versus exemestane plus placebo. One trial is being conducted in the US (NCT02115282) and plans to complete in 2021, while the other trial is being run in China (NCT03538171) and is set to finish in 2020.
###
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO 2018 Congress
Official Congress hashtag: #ESMO18
Disclaimer
This press release contains information provided by the authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of ESMO who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.
References
- Abstract 283O_PR ' Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer ' will be presented by Zefei Jiang during the Presidential Symposium 1 on Saturday, 20 October 2018, 16:30 to 18:20 (CEST) in Room 18 - Hall A2. Annals of Oncology, Volume 29 Supplement 8 October 2018
- Munster PN, Thurn KT, Thomas S, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104(12):1828-1835. doi: 10.1038/bjc.2011.156. Epub 2011 May 10.
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With 18,000 members representing oncology professionals from over 150 countries worldwide, ESMO is the society of reference for oncology education and information. ESMO is committed to offer the best care to people with cancer, through fostering integrated cancer care, supporting oncologists in their professional development, and advocating for sustainable cancer care worldwide.Visit http://www.esmo.org
283O_PR - Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer
Z. Jiang1, W. Li2, X. Hu3, Q. Zhang4, T. Sun5, S. Cui6, S. Wang7, Q. Ouyang8, Y. Yin9, C. Geng10, Z. Tong11, Y. Cheng12, Y. Pan13, Y. Sun14, H. Wang15, T. Ouyang16, K. Gu17, J. Feng18, X. Wang19
1Department of Breast Cancer, 307th Hospital of PLA (AMMS China), Beijing, China, 2Department of Cancer, The First Hospital of Jilin University, Changchun, China, 3Department of Cancer, Fudan University Shanghai Cancer Center, Shanghai, China, 4Department of Cancer, Harbin Medical University Cancer Hospital, Harbin, China, 5Department of Cancer, Liaoning Cancer Hospital, Shenyang, China, 6Department of Cancer, Henan Cancer Hospital, Zhengzhou, China, 7Department of Cancer, Sun yat-sen University Cancer Center, Guangzhou, China, 8Department of Cancer, Hunan Cancer Hospital, Changsha, China, 9Department of Cancer, Jiangsu Province Hospital, Nanjing, China, 10Department of Cancer, Tumor Hospital of Hebei Province, Shijiazhuang, China, 11Department of Cancer, Tianjin Medical University Cancer Hospital, Tianjin, China, 12Department of Cancer, Jilin Cancer Hospital, Changchun, China, 13Department of Cancer, Anhui Province Hospital, Hefei, China, 14Department of Cancer, Jinan Cancer Hospital, Jinan, China, 15Department of Cancer, The Third Hospital of Nanchang, Nanchang, China, 16Department of Cancer, Beijing Cancer Hospital, Beijing, China, 17Department of Cancer, The First Affiliated Hospital of Anhui Medical University, Hefei, China, 18Department of Cancer, Jiangsu Cancer Hospital, Nanjing, China, 19Department of Cancer, Zhejiang Cancer Hospital, Hangzhou, China
Background: Chidamide (CS055/Tucidinostat/Epidaza®) is an oral subtype-selective HDAC inhibitor. An exploratory clinical study has demonstrated the encouraging antitumor activity of chidamide in combination with exemestane in hormone receptor (HR)-positive advanced breast cancer (ABC) patients.
Methods: This randomized, double-blind, placebo-controlled study involved postmenopausal patients with HR-positive, HER2-negative ABC that had failed with tamoxifen and/or nonsteroidal aromatase inhibitor. Eligible patients were randomly assigned (2:1) to two arms (chidamide 30 mg twice a week plus exemestane 25 mg daily or placebo plus exemestane). The primary endpoint was progression-free survival (PFS), assessed by investigator. Secondary endpoints were overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR), and safety.
Results: 365 patients were enrolled at 22 centers in China, with 244 in the chidamide group and 121 in the placebo group. The median PFS was 7.4 months [95% confidence interval (CI), 5.5 to 9.2] with chidamide-exemestane and 3.8 months (95% CI, 3.7 to 5.5) with placebo-exemestane (hazard ratio for disease progression or death, 0.755; 95% CI, 0.582 to 0.978; P=0.0336). ORR were 18.4% and 9.1 (P=0.026), and CBR were 46.7% and 35.5% (P=0.034) in the chidamide group and placebo group, respectively. Overall survival results were not mature at the time of the analysis. The most common grade 3 or 4 adverse events (AE) in the chidamide group were neutropenia (50.8% vs. 2.5% in the placebo group), thrombocytopenia (27.5% vs. 2.5%), and leucopenia (18.8% vs. 2.5%). Serious adverse events occurred in 51 (20.9%) patients in the chidamide group and 7 (5.8%) patients in the placebo group. No treatment-related death was reported.
Conclusions: This is the first oral HDAC inhibitor combined with exemestane in a pivotal clinical study to demonstrate PFS benefit and manageable adverse effect in HR-positive ABC patients progressed after prior endocrine therapy.
Clinical trial identification: NCT02482753.
Legal entity responsible for the study: Jiang Zefei.
Funding: Chipscreen Biosciences Co., Ltd.
Disclosure: All authors have declared no conflicts of interest.
Journal
Annals of Oncology